Explore Publications

The Beijing Olympic Organizing Committee said it was taking corrective measures after a monthlong investigation found that four factories making Olympic merchandise were guilty of labor violations.

Surrounded by darkness, an AK-47 at his side, Jonathon Cote considered his future early last November from Southern Iraq. On Nov. 16, he and four colleagues from Crescent Security Group, a small private firm, were ambushed and taken hostage.

GlaxoSmithKline provides research funding to doctors who write favorable opinions of depression drugs for children, despite evidence from clinical trials that the medication can cause anger and even suicide.

An ambush in Iraq last November left four Americans missing and a string of questions about the firm they worked for.

Follow-up studies on a cleanup effort at the site of a former Ford car factory have shown that there is still a great deal of toxins left in the soil.

Two American civilian contractors who worked on a massive U.S. Embassy construction project in Baghdad told Congress yesterday that foreign laborers were deceptively recruited and trafficked to Iraq to toil at the site, where they experienced physical abuse and substandard working conditions.

A plan to build a new, large coal-fired power plant has proved divisive in the Navajo community in Nevada, with some arguing that it will bring the community millions, while others saying it is a lethal "energy monster" and harbinger of environmental destruction.

The U.S. Congress and the mainstream media are picking up on some of the issues that CorpWatch has been digging into over the last couple of years. Namely, trafficking of workers to Iraq; coal power plants on Diné land; and Iraq reconstruction.

One of the largest American contractors working in Iraq, Bechtel National, met its original objectives on fewer than half of the projects it received as part of a $1.8 billion reconstruction contract, while most of the rest were canceled, reduced in scope or never completed as designed, federal investigators have found in a report released yesterday.

The Food and Drug Administration will ask a panel of outside medical experts Monday whether it thinks GlaxoSmithKline PLC's diabetes drug Avandia should remain on the U.S. market.